Real problems worth solving

Only 37% of U.S. public high schools employ a full-time certified athletic trainer, and roughly one-third of secondary schools have no access to an athletic trainer at all. Approximately 5.9 million high school student-athletes may lack immediate access to a healthcare professional when they are injured during practice or competition. This matters because athletic trainers are the first responders for sports injuries, from concussions to heat stroke to sudden cardiac arrest. Without one present, a coach or parent must make triage decisions they are not trained for. When a concussion goes unrecognized, as studies show up to 50% do without an AT present, the athlete returns to play too early, risking second-impact syndrome, which can cause permanent brain damage or death. When a cardiac arrest happens and no AT is there to activate an emergency action plan and use an AED, survival rates drop dramatically: from 83% with an AT on-site to under 50% without. The downstream consequences compound. Schools without ATs see higher injury rates, longer recovery times, and more athletes who quit sports entirely due to mismanaged injuries. Parents in these districts face unexpected medical bills because injuries that could have been prevented or treated on-site instead become emergency room visits. Rural and low-income communities are disproportionately affected: almost 8 in 10 schools with low AT availability are in rural or inner-city areas. This problem persists because no U.S. state mandates that high schools employ an athletic trainer. Of the 48 states surveyed in 2024, 37 (77%) had no sideline medical coverage mandate of any kind. School boards view athletic trainers as a budget line item rather than a safety requirement, and athletics budgets prioritize coaching salaries, equipment, and facilities over healthcare staffing. The structural root cause is that high school sports governance treats medical coverage as optional rather than as a prerequisite for fielding a team.

A growing market of at-home tattoo removal products -- creams, chemical peels, DIY laser devices, and salabrasion kits -- promises painless, affordable tattoo removal without clinic visits. None of these products are FDA-approved for tattoo removal. The creams typically contain skin-bleaching agents like hydroquinone or trichloroacetic acid (TCA) that may lighten the skin around the tattoo but cannot reach ink deposited in the dermis layer. DIY laser devices sold online operate at unregulated power levels and lack safety features found in clinical devices. The FDA has explicitly warned that no at-home methods are approved. The harm is significant and well-documented. Chemical agents cause chemical burns, permanent scarring, and infections. DIY lasers can cause retinal damage from unprotected laser exposure and severe skin burns from incorrect settings. Salabrasion -- rubbing salt into the skin to abrade it -- essentially creates an open wound and carries serious infection risk. Patients who injure themselves with at-home methods often end up in emergency rooms, where treatment costs far exceed what professional laser removal would have cost. This market exists because professional removal is prohibitively expensive and time-consuming for many people. When the legitimate solution costs $3,000-$10,000 and takes two years, desperate consumers turn to cheap alternatives promising results for $50 in two weeks. The products persist on the market because the FDA's enforcement resources are limited, e-commerce platforms do not verify product safety claims, and the products are often marketed from overseas where US regulatory authority cannot reach. Social media amplifies the problem, with influencer-promoted removal creams generating millions of views despite having no clinical evidence of efficacy.

While modern Q-switched and picosecond lasers have reduced scarring rates, the risk is not zero. A study of 1,041 patients published in the Journal of Clinical and Aesthetic Dermatology found a 0.28% hypertrophic scarring rate with Q-switched Nd:YAG lasers, but broader analyses that include all removal methods and less experienced operators report scarring rates of 18-25%. Non-laser methods like dermabrasion, chemical peels (using lactic acid, salicylic acid, or phenol), and surgical excision carry substantially higher scarring risk. The catch-22 is this: a person who wants to remove a tattoo because it causes them social, professional, or psychological harm may end up with a scar that causes the same problems. A raised, discolored scar on the forearm is just as visible as the tattoo it replaced, and arguably more stigmatized because scars raise questions about self-harm or injury. Patients are rarely given realistic probability estimates of this outcome before beginning treatment, partly because outcomes depend on unpredictable factors (individual healing response, keloid tendency, sun exposure during treatment) and partly because clinics have a financial incentive to start treatment rather than discourage it. This persists because there is no standardized informed consent process for tattoo removal. Unlike surgery, where detailed risk disclosures are legally mandated and well-established, tattoo removal consent varies wildly by clinic. Some clinics provide extensive education; others have patients sign a single page and begin treatment. The lack of federal oversight means there is no required adverse outcome registry, so the true population-level scarring rate remains poorly quantified.

The FDA has not approved any pigments for injection into the skin for cosmetic tattoo purposes. Tattoo inks are technically classified as cosmetics, but until the Modernization of Cosmetics Regulation Act of 2022, the FDA had virtually no enforcement authority over them. A 2024 study published in Analytical Chemistry found that only 6 out of 54 inks analyzed matched their labeled composition accurately, and 45 inks contained unlisted pigments or additives including polyethylene glycol. Published research has found inks containing heavy metals such as cadmium, lead, mercury, and arsenic, as well as pigments originally designed for printer toner and car paint. This matters for removal because unknown ink composition makes laser treatment unpredictable. Different pigments respond to different laser wavelengths, and if the practitioner does not know what is actually in the tattoo (because neither the client nor the tattoo artist knew), they cannot optimize treatment settings. Worse, some metallic pigments can oxidize under laser exposure, turning darker instead of lighter -- a phenomenon called paradoxical darkening that is particularly common with cosmetic tattoos (permanent makeup) containing iron oxide or titanium dioxide. The structural cause is a decades-long regulatory gap. The FDA historically deprioritized tattoo ink regulation because it did not receive enough adverse event reports to justify action -- but adverse events were underreported precisely because there was no mandatory reporting system. The 2022 legislation gave the FDA recall authority and required annual ingredient labeling updates, but enforcement remains in early stages and the existing stock of unregulated inks will be in people's skin for decades.

Visible tattoos on the face, neck, and hands remain a significant barrier to employment. A 2018 LinkedIn survey found that 88% of HR managers believe tattoos can limit career prospects, and 40% admitted rejecting suitable candidates specifically because of visible tattoos. For formerly incarcerated individuals -- 65% of whom have tattoos according to prison population studies, with 75% of re-incarcerated inmates having tattoos -- visible ink creates a compounding barrier on top of a criminal record. This employment barrier drives real economic damage. A person with a face or neck tattoo who cannot get hired is more likely to return to criminal activity, substance use, or homelessness. Studies on recidivism suggest that stable employment is one of the strongest predictors of successful reentry, yet the tattoo barrier can prevent that employment from ever starting. The economic cost to society -- through re-incarceration at $30,000-$60,000 per year per inmate -- far exceeds the $3,000-$5,000 cost of removing a face tattoo. Free and low-cost tattoo removal programs exist (Jails to Jobs maintains a directory, Removery's INK-nitiative serves formerly incarcerated individuals) but they are overwhelmed by demand. Programs report multi-month to multi-year waitlists, and because each patient needs 6-12 sessions over 12-18 months, throughput is inherently limited. The programs are funded primarily by charity and corporate partnerships, not by the criminal justice system that would benefit most from investing in them. This is a classic case where the institution that bears the cost of the problem (the prison system) is disconnected from the institution that could solve it (removal clinics).

Human traffickers routinely brand their victims with tattoos -- names, gang symbols, barcodes, or ownership marks -- as a form of control and identification. When survivors escape, these tattoos become permanent reminders of their trauma and can identify them to their former traffickers, putting them in ongoing physical danger. Yet the cost of professional laser removal ($2,500-$10,000+) is far beyond the means of most trafficking survivors, who often emerge from exploitation with no savings, no credit, and no insurance. The psychological impact is devastating. Survivors report that branded tattoos trigger PTSD episodes, interfere with forming new relationships, and create shame that prevents them from seeking employment or social services. A survivor with a trafficker's name tattooed on her neck cannot simply 'move on' -- she carries a visible marker of her exploitation every time she looks in a mirror or meets someone new. The multi-year removal timeline adds further cruelty: even those who access free removal programs must endure 12-18 months of treatment while carrying the brand. The structural gap is that the healthcare system treats trafficking-related tattoo removal identically to elective cosmetic removal. No federal program exists to fund removal for verified trafficking survivors. The burden falls entirely on a small number of nonprofits -- Unbranded (which has treated only 43 survivors total since 2022), Removery's INK-nitiative, Chains Break, and a handful of others. These programs are underfunded and geographically concentrated, leaving most survivors without access. NYC's ACS launched a pilot program in 2018 but scaling has been minimal.

In the United States, there is no federal licensing standard for who can operate a laser tattoo removal device. Regulation is left entirely to individual states, creating a patchwork where requirements range from 'only a physician may fire the laser' (New Jersey, Ohio) to 'virtually anyone can operate it' (Colorado, parts of New York). In loosely regulated states, a person can take a weekend certification course and begin performing laser procedures on paying clients the following Monday, with minimal understanding of skin anatomy, laser physics, or complication management. This regulatory gap directly harms patients. An undertrained operator who uses incorrect laser settings can cause third-degree burns, permanent scarring, hypopigmentation, or infection. Because tattoo removal typically occurs in medical spas and aesthetic clinics rather than hospitals, there is often no immediate medical backup when complications occur. Patients who suffer adverse outcomes in loosely regulated states may have limited legal recourse because the operator technically met the (minimal) state requirements. This persists because laser tattoo removal falls into a regulatory gray zone between medicine and cosmetics. State medical boards focus on physicians, state cosmetology boards focus on beauty services, and laser procedures fit neatly into neither category. The tattoo removal industry itself is fragmented -- dominated by small independent clinics with no trade association powerful enough to push for uniform national standards. Meanwhile, device manufacturers benefit from the status quo because fewer regulations mean more potential buyers for their equipment.

People with Fitzpatrick skin types IV-VI (medium brown to dark brown and black skin) face significantly higher risks of hypopigmentation (lighter patches) and hyperpigmentation (darker patches) after laser tattoo removal. The laser energy that targets ink pigment also gets absorbed by melanin in the surrounding skin, causing collateral damage. For darker-skinned patients, this means treatments must use lower energy settings, require more sessions, and still carry a meaningful risk of permanent skin discoloration that can be more disfiguring than the original tattoo. This disparity matters because tattoo prevalence does not track with skin tone -- people of all backgrounds get tattoos. Yet the foundational laser technology was developed and calibrated primarily on lighter skin. Darker-skinned patients face a cruel choice: accept the tattoo permanently, risk visible scarring and discoloration, or pay significantly more for extended treatment courses with specialized (and rarer) providers who have experience with higher Fitzpatrick types. According to Pew Research, 30% of tattooed Hispanic adults report tattoo regret, the highest rate of any demographic group, yet they face greater removal barriers. The structural reason is that dermatological laser research has historically underrepresented darker skin tones in clinical trials and device development. Q-switched Nd:YAG lasers at 1064nm are safer for darker skin because they bypass melanin more effectively, but many clinics still use older or cheaper devices not optimized for diverse skin types. Picosecond lasers reduce thermal injury and are better for darker skin, but they cost $150,000-$300,000 per device, pricing out smaller clinics that serve diverse communities.

Black tattoo ink absorbs all wavelengths of laser light, making it the easiest color to remove. But green, blue, teal, yellow, and white inks only absorb narrow wavelength bands, which means standard Q-switched lasers (which typically offer only two wavelengths, 1064nm and 532nm) cannot effectively shatter these pigments. Patients with colorful tattoos often see their black ink fade while greens and blues remain stubbornly visible, creating a ghostly partial image that can look worse than the original. This is a significant problem because the tattoo industry has trended heavily toward colorful, multi-ink designs over the past two decades. Watercolor tattoos, full-color sleeves, and vibrant illustrative work are more popular than ever. But the removal technology has not kept pace. A patient who got a colorful sleeve in their twenties and wants it removed in their thirties faces a fundamentally harder, longer, more expensive process than someone with simple black linework -- and many clinics will not disclose this up front. The structural cause is a mismatch between the tattoo ink industry and the laser removal industry. Tattoo ink manufacturers have no incentive to make their inks removable -- in fact, permanence is a selling point. Meanwhile, laser manufacturers are constrained by physics: each ink color requires a specific wavelength to absorb the energy, meaning a truly universal removal laser would need 4-6 wavelengths, dramatically increasing device cost. Newer picosecond lasers like PicoSure and PicoWay improve outcomes for some colors but still struggle with light green, yellow, and white.

Laser tattoo removal is not a single procedure but a grueling multi-session process. Most tattoos require 6 to 12 sessions, and each session must be spaced 6 to 8 weeks apart to allow the skin to heal and the immune system to flush broken ink particles. For stubborn tattoos with dense or multi-colored ink, 15-20 sessions may be needed. Simple arithmetic reveals the problem: 10 sessions at 8-week intervals means 80 weeks -- over a year and a half of treatment for a single tattoo. This timeline creates enormous friction for people who need removal urgently. A trafficking survivor branded with a pimp's name cannot wait 18 months to stop being visually identified. A job seeker with a face tattoo cannot pause their employment search for two years. A person experiencing severe tattoo-related allergic reactions must endure ongoing symptoms for the entire treatment duration. The extended timeline also causes high dropout rates, as patients lose motivation, move, change financial circumstances, or simply cannot sustain the ongoing cost and pain. The reason this timeline exists is biological, not technological. The laser shatters ink particles into fragments, but the body's macrophages must then physically transport those fragments to lymph nodes for disposal. This immune-mediated clearance process cannot be meaningfully accelerated without risking tissue damage. No amount of laser power can speed up the body's waste disposal system. Research into adjunctive methods (perfluorodecalin patches, R20 multi-pass techniques) has shown modest improvements but nothing that fundamentally changes the months-to-years timeline.

Health insurance companies classify tattoo removal as a cosmetic procedure, making it ineligible for coverage under virtually all standard health plans. The American Society of Plastic Surgeons reports an average cost of $423 per session, and most tattoos require 6-12 sessions to fully remove. This means a single tattoo removal can cost $2,500 to $10,000 or more, paid entirely out of pocket. This matters because tattoo regret affects roughly 24% of tattooed Americans -- about 21 million people according to a 2023 Pew Research study. For many of these individuals, the tattoo is not a cosmetic nuisance but a genuine source of psychological distress, employment discrimination, or a branding mark from trafficking or gang involvement. A formerly incarcerated person with a face tattoo who cannot get hired is not seeking a cosmetic enhancement -- they are seeking economic survival. Yet the insurance system treats all tattoo removal identically as elective vanity. The structural reason this persists is that insurance classification systems were designed around a binary of 'medically necessary' versus 'cosmetic,' and tattoo removal was bucketed into cosmetic decades ago when tattoos were rare and removal was uncommon. Updating these classifications requires actuarial review, lobbying, and regulatory change that no single constituency has enough power to push through. The result is a $1.13 billion industry (2024, Fortune Business Insights) built almost entirely on cash-pay patients, with the highest burden falling on the people least able to afford it.

Despite maintaining a National Bridge Inventory with detailed data on every bridge's condition, there is no national system for prioritizing which bridges should be replaced first. Each state, county, and city makes its own prioritization decisions independently, using different criteria, different analytical tools, and different political considerations. A structurally deficient bridge on a critical freight corridor in one state may wait decades for replacement while a less critical bridge in a neighboring state is replaced because it had a more effective political advocate. This matters because bridge replacement funding is scarce relative to need, and misallocation of scarce resources means more preventable failures, more unnecessary weight restrictions, and more economic harm than necessary. If the available $20 billion in annual bridge spending were allocated to maximize safety and economic benefit nationally, the outcome would be measurably better than the current system where each jurisdiction optimizes locally. The practical impact is visible in the data: some states have reduced their structurally deficient bridge counts dramatically (e.g., Pennsylvania's aggressive bridge bundling program), while others have made little progress despite similar or worse starting conditions. The difference is not funding levels alone; it is management capacity, political will, and prioritization methodology. Best practices exist but do not propagate because there is no national framework to identify and disseminate them. This problem persists because transportation infrastructure in the US is constitutionally and politically a state and local responsibility. The federal government provides funding and sets minimum standards but does not direct how states prioritize their bridge programs. Any attempt to create a national prioritization system would be seen as federal overreach by state DOTs that guard their programmatic independence. The Bipartisan Infrastructure Law (2021) increased bridge funding significantly but still distributes it by formula rather than by need. The structural root cause is federalism itself. The US system distributes transportation funding through formulas based primarily on lane-miles and fuel tax contributions, not on bridge condition or replacement urgency. A state with newer bridges receives nearly as much bridge formula funding per capita as a state with a crumbling inventory. The Bridge Investment Program, a competitive grant created by the Infrastructure Law, represents a modest step toward need-based allocation, but it funds only a fraction of total bridge investment and requires applications that smaller jurisdictions struggle to produce.

Every bridge in the US must have a load rating: a calculated determination of the maximum load the bridge can safely carry. Many bridges, particularly older ones owned by local agencies, still carry load ratings calculated using methods and assumptions from the AASHTO Standard Specifications that date back to the 1940s. These calculations often use nominal material strengths rather than tested strengths, ignore composite action between the deck and girders, and apply conservative distribution factors that may not reflect actual bridge behavior. This matters because inaccurate load ratings lead to one of two costly outcomes. If the rating is too conservative, the bridge gets an unnecessary weight restriction, forcing detours and economic harm when the bridge could actually carry legal loads safely. If the rating is too aggressive (which is rarer but happens when original design drawings are lost and assumptions are made), vehicles heavier than the bridge can safely carry are allowed to cross it, creating a safety risk. The practical pain is felt most acutely by the trucking and agriculture industries. A bridge rated at 20 tons that could actually carry 40 tons if properly re-rated forces every loaded truck to detour. Across a state with hundreds of conservatively rated bridges, the cumulative economic impact is substantial. Re-rating a single bridge using modern methods (refined analysis, material testing, load testing) costs $10,000 to $50,000, a fraction of the cost of the detours it would eliminate. This problem persists because load rating is not glamorous work. It does not produce a ribbon-cutting photo opportunity. It requires structural engineers with bridge-specific expertise, and the workload of re-rating thousands of bridges is enormous. State DOTs prioritize new ratings for bridges being designed or reconstructed, not re-ratings of existing bridges whose ratings, however outdated, are technically compliant. The structural root cause is that FHWA requires bridges to have a load rating but does not require those ratings to be updated using current methods. An agency can comply with federal requirements using a load rating calculated in 1985 using 1970s methods. There is no federal mandate to re-evaluate ratings when analytical methods improve, when material testing becomes available, or when traffic patterns change. The rating is treated as a static number rather than a living engineering assessment.

States in the northern US and snowbelt regions apply approximately 24 million tons of road salt annually. This salt dissolves in meltwater and penetrates concrete bridge decks, reaching the reinforcing steel inside. Once chloride concentrations at the rebar level exceed a threshold (typically 1.0-1.5 pounds per cubic yard of concrete), the steel begins to corrode. Corroding rebar expands, cracking the concrete from within, which admits more salt, accelerating the cycle. This process is cutting 15-25 years off the expected lifespan of bridge decks throughout the northern states. This matters because bridge decks are the most expensive component to repair or replace, typically costing $500,000 to $2 million for a single bridge. When salt damage forces a deck replacement after 30 years instead of the designed 50 years, the lifecycle cost of the bridge increases dramatically. Across the tens of thousands of bridges in salt-application states, this represents billions of dollars in premature replacement costs. The compounding effect is that salt damage is not limited to decks. Salt-laden runoff attacks steel girders, bearings, pier caps, and substructure elements. Expansion joints leak, allowing salt water to drip onto girders below. Entire bridges can become structurally compromised from what began as a surface-level deck issue. The repair costs cascade as each component is damaged in sequence. This problem persists because road salt is extremely cheap (about $60 per ton) and extremely effective at preventing ice-related accidents. Alternatives like calcium magnesium acetate are 10-30 times more expensive. From a DOT's perspective, the cost of salt damage to bridges is a future capital expense borne by a different budget, while the cost of a fatal ice accident is immediate and politically devastating. The incentive is to salt heavily and deal with bridge damage later. The structural root cause is that the entities that apply salt (maintenance divisions) and the entities that repair salt damage (bridge divisions) operate on separate budgets with separate incentives within the same DOT. There is no internal pricing mechanism that charges the maintenance division for the bridge damage caused by its salt application. If maintenance had to pay bridge repair costs, salt application rates would be optimized rather than maximized. Some states have begun experimenting with anti-icing strategies and reduced-salt approaches, but cultural change in winter maintenance is slow.

Of the 617,000 bridges in the United States, approximately 56% are owned by local governments: counties, cities, towns, and townships. Many of these jurisdictions, particularly in rural areas, have no licensed engineer on staff. A township of 2,000 people may own a dozen bridges and have a road crew of three people with no engineering training. They are responsible for maintaining structures that, if they fail, could kill people. This matters because bridge management requires engineering judgment that these jurisdictions simply do not have. Deciding whether a crack is structural or cosmetic, whether a scour hole is progressing, whether a bridge can safely carry a school bus: these are engineering questions with life-safety implications. Without an engineer, these decisions are made by elected officials or road foremen based on gut instinct, or they are not made at all. The downstream pain is that small municipalities cannot effectively participate in federal bridge programs. Applying for federal bridge replacement funding requires engineering studies, environmental reviews, and right-of-way documentation that cost $100,000 to $500,000 before a single shovel hits the ground. A small town cannot front that money, and even if it could, it would not know how to manage the process. The result is that the jurisdictions with the worst bridges are the least able to access the funding to fix them. This problem persists because there is no mechanism to aggregate small bridge owners into units large enough to support professional engineering staff. Some states have created bridge programs that provide engineering support to local governments, but these are underfunded and oversubscribed. The alternative, transferring bridge ownership to states or counties, is politically difficult because it requires the receiving entity to accept both the bridge and the liability. The structural root cause is the American system of hyper-local government. The US has over 89,000 local governments, many of which were created in the 19th century when bridges were simple wooden structures that any carpenter could maintain. The governmental structure has not adapted to the reality that modern bridges are engineered structures requiring professional management. Nobody deliberately decided that a township of 500 people should be responsible for maintaining a 200-foot concrete bridge; it happened incrementally as the bridge was upgraded from a wooden structure to a concrete one while the governmental structure remained unchanged.

Approximately 18,000 bridges in the United States are classified as fracture-critical, meaning they contain steel members whose failure would cause the collapse of the bridge. These bridges have no structural redundancy: if one key member cracks or fails, there is no alternate load path, and the bridge comes down. The I-35W bridge that collapsed in Minneapolis in 2007 was a fracture-critical design. This matters because fracture-critical bridges require a fundamentally different safety approach than redundant bridges. On a redundant bridge, a cracked member redistributes load to other members, giving inspectors time to find and repair the damage. On a fracture-critical bridge, there is no second chance. The inspection must catch every crack before it propagates to failure, which is an unrealistic standard given the limitations of visual inspection and the difficulty of detecting subsurface fatigue cracks. The practical consequence is that these bridges require more frequent and more sophisticated inspection, including hands-on inspection of every fracture-critical member, often requiring special access equipment and traffic closures. This makes them disproportionately expensive to maintain. Yet many are also high-traffic bridges carrying interstate highways, so closures for inspection cause significant disruption. This problem persists because replacing a fracture-critical bridge is enormously expensive, often $50 million to $500 million for major crossings, and the bridge is typically still functional. It is politically impossible to justify closing and replacing a bridge that is carrying traffic today because of a theoretical risk of sudden failure. The calculus only changes after a failure, by which point it is too late. The structural root cause is that fracture-critical designs were standard practice in the 1950s through 1970s because they used less steel and were cheaper to build. The engineering profession understood the theoretical risk but did not appreciate how difficult it would be to maintain zero-tolerance inspection standards over a 75-year bridge life. Modern bridge design avoids fracture-critical configurations, but the legacy fleet of 18,000 bridges will be in service for decades to come.

Scour, the erosion of riverbed material around bridge foundations by flowing water, is the leading cause of bridge failure in the United States. FHWA estimates that 60% of all bridge failures are scour-related. Unlike cracking or corrosion, which are visible, scour happens underwater and underground, invisibly undermining the foundation that holds the entire bridge up. A bridge can look perfectly fine from the surface while its foundations are critically compromised. This matters because scour failures tend to be sudden and total. When a bridge foundation loses enough soil support, the pier or abutment can shift or collapse with little warning, often during flood events when the bridge is most needed and rescue is most difficult. The Schoharie Creek Bridge collapse in New York in 1987, which killed 10 people, was caused by scour that had gone undetected despite inspections. The problem is compounded by climate change. More intense rainfall events and changing flood patterns are increasing scour risk on bridges that were designed for historical hydrology. A bridge that was safe under the 100-year flood event calculated in 1970 may not be safe under the 100-year flood event recalculated with current climate data. Yet most bridges have not been re-evaluated for updated flood risks. This problem persists because underwater inspection is expensive, technically difficult, and dangerous. Inspecting a bridge foundation for scour requires divers or sonar equipment, and conditions are often poor: murky water, strong currents, debris. Many agencies only perform underwater inspections on a 5-year cycle, and some bridges classified as scour-critical have never had a full underwater inspection of their foundations. The structural root cause is that bridge inspection standards were originally designed around what inspectors could see from the surface. The National Bridge Inspection Standards were created after the 1967 Silver Bridge collapse, which was caused by a visible defect (a corroded eyebar). The inspection framework is inherently biased toward detecting visible, above-water defects and poorly suited to detecting invisible, below-water ones. Fixed scour monitoring instrumentation exists but is installed on fewer than 5% of scour-vulnerable bridges due to cost.

State and local transportation agencies face a recurring dilemma: spend money repairing a deteriorating bridge to extend its life by 10-15 years, or spend 3-5 times more to replace it with a new bridge that will last 75 years. In theory, lifecycle cost analysis should make this decision straightforward. In practice, agencies systematically choose repair over replacement even when replacement is the better long-term investment, because they lack the upfront capital for replacement and their budgets are annual. This matters because repeated repairs on a bridge nearing the end of its useful life represent wasted money. A bridge that receives three rounds of $1.5 million deck repairs over 20 years before ultimately being replaced for $8 million has cost $12.5 million total, when a single $8 million replacement 20 years earlier would have saved $4.5 million and provided a safer, wider, higher-capacity bridge for the entire period. FHWA estimates that deferred maintenance and repair-patching costs 4-5 times more over a bridge's lifecycle than timely replacement. The downstream consequence is that agencies become trapped in a cycle of reactive maintenance. Their entire bridge budget goes to emergency repairs and minimum-viable patches on the worst bridges, leaving nothing for proactive replacement of bridges that are deteriorating but not yet critical. This guarantees a perpetual crisis state where the agency is always firefighting. This problem persists because of how government budgets work. Annual appropriations make it nearly impossible to save up for a large capital project. A county engineer who defers a $500,000 repair this year to save toward a $5 million replacement will have that unspent money reallocated by the county board. Federal grant programs can help, but they have multi-year application timelines and uncertain outcomes, making it irrational for a local agency to gamble its maintenance budget on a grant it might not receive. The structural root cause is the mismatch between bridge lifecycles (50-100 years) and political/budget cycles (1-4 years). No elected official benefits from investing in a bridge replacement whose payoff will not be fully realized for decades. The incentive is to spend the minimum necessary to keep the bridge open during one's term and leave the replacement decision to a successor.

Over 80,000 bridges in the United States carry weight restrictions that limit the size of vehicles that can cross them. These restrictions disproportionately affect rural areas, where a single bridge may be the only crossing for miles. When a bridge is weight-restricted, heavy vehicles like grain trucks, logging trucks, milk tankers, and farm equipment must detour, sometimes adding 20 to 50 miles to a one-way trip. This matters because agriculture and natural resource industries depend on heavy vehicle access. A corn farmer who cannot drive a loaded grain truck across the nearest bridge to reach the elevator must either make multiple trips with lighter loads, burning more fuel and time, or drive a long detour on roads that may also be in poor condition. The USDA estimates that weight-restricted bridges cost rural economies hundreds of millions of dollars annually in increased transportation costs. The compounding pain is that these detours accelerate the deterioration of the detour routes. When heavy trucks are forced onto secondary roads that were not designed for heavy loads, those roads break down faster, creating a cascading maintenance burden. The community that could not afford to fix one bridge now has to fix the bridge and the roads its detour traffic destroyed. This problem persists because rural bridges are overwhelmingly owned by counties and townships, the poorest levels of government. A rural county with a few thousand residents and a property tax base of modest farmland simply cannot generate the revenue to replace a $3 million bridge. Federal aid programs exist but require local matching funds that small jurisdictions cannot provide, and the application process is complex enough to require engineering consultants that small counties also cannot afford. The structural root cause is that the US built an enormous network of rural bridges in the mid-20th century, many designed for lighter vehicles than today's agricultural equipment. These bridges are now 60 to 80 years old and reaching the end of their design life simultaneously. The funding model assumed future generations would have the resources to replace them, but rural population decline and agricultural consolidation have shrunk the tax bases that were supposed to pay for replacements.

Federal law requires most highway bridges to be inspected at least every 24 months, but state and local agencies routinely miss these deadlines. A 2023 Government Accountability Office report found that thousands of bridges had overdue inspections, with some states reporting inspection completion rates below 90%. The Federal Highway Administration identified recurring issues with inspection timeliness across multiple states. This matters because the entire bridge safety framework depends on inspections catching deterioration before it becomes dangerous. When inspections fall behind, defects go undetected. A bridge that was in fair condition two years ago may have developed serious corrosion, scour damage from flooding, or fatigue cracking in steel members. Without a timely inspection, nobody knows. The inspection is the only mechanism the system has for catching problems between the day a bridge is built and the day it fails. The downstream consequence is that weight restrictions, closures, and emergency repairs happen reactively instead of proactively. When a long-overdue inspection finally occurs and finds serious defects, the bridge may need to be immediately closed or weight-restricted, disrupting traffic with no warning. Proactive inspection would have caught the deterioration earlier, when repair was cheaper and closures could be planned. This problem persists because there are not enough qualified bridge inspectors. Bridge inspection requires specialized training and certification under the National Bridge Inspection Standards, and the work is physically demanding, often requiring climbing, rope access, or working over water. Many state DOTs struggle to recruit and retain inspectors because private-sector engineering jobs pay more and involve less fieldwork. Rural states with large bridge inventories are hit hardest. The structural root cause is that the federal government mandates inspections but does not fund them directly. States must pay for inspections out of their general transportation budgets, where inspection competes with construction, repaving, and other more politically visible activities. There is no dedicated federal funding stream for bridge inspection, and no meaningful enforcement mechanism when states miss deadlines beyond stern letters from FHWA.

The American Society of Civil Engineers reports that 46,154 bridges in the United States are classified as structurally deficient, meaning key structural elements are in poor or worse condition. That is roughly 7.5% of the nation's 617,000 bridges. Americans cross these bridges 178 million times every single day. This matters because structurally deficient does not mean the bridge will collapse tomorrow, but it means the bridge has deteriorated to the point where load-carrying capacity is reduced, maintenance costs are escalating, and the risk of sudden failure is materially higher than for bridges in fair or good condition. When a structurally deficient bridge does fail, the consequences are catastrophic: the 2007 I-35W bridge collapse in Minneapolis killed 13 people and injured 145, and the economic disruption from the closed crossing lasted years. The deeper pain is that there is no credible timeline to fix these bridges. At the current pace of repair and replacement, ASCE estimates it would take over 40 years to clear the backlog. Meanwhile, bridges continue to deteriorate faster than they are being repaired, so the backlog is effectively growing. State DOTs know which bridges are worst, but they lack the funding and workforce to act. This problem persists because bridge funding in the US is fragmented across federal, state, and local governments, with no single entity accountable for ensuring every bridge meets minimum standards. The federal Highway Bridge Program provides formula funding, but states have wide discretion to spend it on other transportation priorities. Local governments own 56% of all bridges but receive a disproportionately small share of federal transportation dollars. In the first place, the structural root cause is that bridges are invisible infrastructure. Unlike potholes or congested highways, a deteriorating bridge looks fine until it doesn't. Voters and politicians do not rally around bridge maintenance because the failure mode is rare but catastrophic rather than frequent and visible, creating a classic underinvestment in low-probability, high-consequence risk.

During the COVID-19 pandemic, pharmacies administered the majority of vaccinations in the United States -- but 111 rural counties, mostly between the Mississippi River and the Rocky Mountains, had no pharmacy capable of giving vaccines at all. These same communities had no alternative immunization infrastructure: no health department clinic with vaccine storage, no hospital outpatient pharmacy, no mobile vaccination unit with regular routes. The result was a vaccination coverage gap of nearly 7 percentage points between rural counties (38.9%) and urban counties (45.7%) for COVID-19 vaccines. This is not just a COVID-19 problem. Pharmacies have become the primary immunization site for routine vaccinations including flu, shingles, pneumonia, RSV, and childhood boosters. The PREP Act expanded pharmacists' authority to administer vaccines precisely because pharmacies are more accessible than doctor's offices for most Americans. But this public health strategy assumed ubiquitous pharmacy access. In pharmacy deserts, the entire immunization infrastructure collapses because it was built on a retail pharmacy foundation that no longer exists in those communities. The public health consequences extend beyond the unvaccinated individuals themselves. Immunization rates below herd immunity thresholds in pharmacy desert communities create reservoirs for infectious disease that can seed outbreaks in surrounding areas. Measles, pertussis, and influenza do not respect county boundaries. A pharmacy desert in one county becomes a public health risk for the entire region. This problem persists because the United States delegated a core public health function -- population-level immunization -- to private-sector retail infrastructure without guaranteeing that infrastructure's permanence. Unlike the UK's National Health Service, which operates vaccination clinics as a government function, the US depends on pharmacies whose existence is determined by market forces. When the market withdraws, the public health function disappears with it, and no government entity has the standing infrastructure to step in quickly. Rebuilding public immunization capacity in 111+ counties would require sustained funding and political will that has not materialized.

Rural communities have higher opioid prescribing rates than urban areas but dispense naloxone -- the overdose-reversal medication -- at much lower rates. This deadly mismatch is driven in part by pharmacy deserts: 630 rural counties lack any retail pharmacy, meaning residents in those areas cannot walk in and obtain naloxone even though it became available over-the-counter in 2023. Even in rural counties that have pharmacies, pharmacists are more likely than their urban counterparts to report moral objections to providing naloxone, and many rural pharmacies do not stock it consistently. The consequences are measured in deaths. Opioid-involved overdose deaths in rural areas have been rising since the mid-2000s, yet the infrastructure to prevent those deaths -- pharmacy-based naloxone distribution, buprenorphine dispensing, and medication-assisted treatment access -- is thinnest precisely where the crisis is worst. When someone overdoses in a rural community without a nearby pharmacy, the window for naloxone administration (typically 1-3 minutes for optimal effectiveness) is consumed by the time it takes for EMS to arrive -- and EMS coverage in many rural areas is itself inconsistent, with volunteer crews and response times exceeding 30 minutes. The pharmacy desert exacerbates the opioid crisis through a second mechanism: lack of access to medication-assisted treatment (MAT). Buprenorphine and methadone dispensing requires pharmacy infrastructure, and pharmacies in rural areas are less likely to participate in MAT programs due to stigma, regulatory burden, and low patient volume. This means that patients seeking recovery must travel long distances to access treatment, creating a barrier that many cannot overcome, leading to relapse and continued overdose risk. This problem persists because naloxone distribution and MAT access are treated as separate policy issues from pharmacy access. Public health campaigns to expand naloxone availability assume there is a pharmacy to distribute it from. Opioid crisis funding flows to treatment programs without addressing the physical infrastructure gap that prevents those programs from reaching the communities most in need. The structural root cause is a healthcare system that depends on private-sector pharmacy infrastructure for public health functions without ensuring that infrastructure exists everywhere it is needed.

The standard industry response to pharmacy closures is that mail-order pharmacy can fill the gap. In reality, mail-order is unsuitable or inaccessible for large segments of the population most affected by pharmacy deserts. Controlled substances like opioid pain medications cannot be mailed in most cases. Temperature-sensitive medications including insulin and biologics face cold-chain integrity risks -- a study found that none of five common packaging technologies maintained the required 36-46 degrees Fahrenheit range during the first 24 hours of shipping, and the critical last-mile delivery window exposes medications to extreme temperatures when left on doorsteps. Delivery times of 3-14 business days are unacceptable for acute prescriptions like antibiotics or rescue inhalers. Beyond logistics, mail-order pharmacy eliminates the clinical interaction that makes community pharmacies a healthcare access point. Pharmacists catch an estimated 2 billion potential medication errors per year through face-to-face counseling, drug utilization reviews, and real-time consultations with prescribers. A mail-order pharmacist reviewing a prescription on screen does not see the patient's physical condition, does not notice the signs of a drug interaction manifesting, and does not have the relationship context to ask probing questions. For elderly patients managing five or more medications -- a group that includes 40% of Americans over 65 -- this personal clinical relationship is a safety net, not a convenience. Mail-order also assumes stable housing with a secure delivery location, reliable internet or phone access to place orders, and the cognitive and organizational capacity to plan refills two weeks in advance. Homeless individuals, people in domestic violence shelters, patients with cognitive decline, and those in unstable housing situations cannot reliably receive mail-order medications. These are precisely the populations with the highest healthcare needs and the least ability to travel to distant pharmacies. This problem persists because mail-order pharmacy is enormously profitable for PBMs -- it eliminates the independent pharmacy middleman entirely and captures the full dispensing margin. PBMs have a direct financial incentive to promote mail-order as a substitute for local pharmacy access, regardless of whether it actually serves the patient population's needs. The narrative that mail-order solves the pharmacy desert problem provides political cover for allowing brick-and-mortar closures to continue unchecked.

The pharmacy workforce is in crisis. A 2021 ASHP survey found that a majority of pharmacy administrators reported technician turnover rates of 21-30%, with nearly one in ten reporting losses exceeding 41% of their technician staff. Average hourly wages for pharmacy technicians range from just $16.57 to $24.53 depending on practice setting -- barely above retail minimums in many markets. The result is a vicious cycle: low pay drives turnover, turnover increases workload on remaining staff, increased workload causes burnout and errors, and burnout drives more turnover. This staffing crisis has direct, visible consequences for patients. Retail chains including Rite Aid and Walgreens have reduced pharmacy operating hours because they cannot staff their counters. Pharmacies that remain open are processing the same volume of prescriptions with fewer hands, leading to longer wait times, delayed prescription fills, and increased risk of dispensing errors. When a pharmacy that used to be open 12 hours a day cuts to 8 hours, the working-hour patients who could only visit in the evening lose access entirely. The staffing shortage compounds the closure crisis. A pharmacy that cannot hire enough technicians to maintain safe operations may choose to close rather than risk liability from medication errors. In rural areas where the labor pool is already thin, a single technician quitting can trigger a cascade: the pharmacist cannot safely operate alone, hours are cut, patients start going elsewhere, volume drops, revenue falls, and the pharmacy becomes financially unviable. This problem persists because pharmacy technician compensation has not kept pace with the demands of the role or competing opportunities in other sectors. A warehouse worker at Amazon earns comparable or higher wages without the liability of handling controlled substances. Pharmacy chains have resisted raising wages because their margins are already compressed by PBM reimbursement rates. The training pipeline is also constrained: pharmacy technician certification programs are underfunded and produce fewer graduates than the market demands. Until the economics of the entire pharmacy reimbursement chain are restructured, there is no funding source to raise technician wages to competitive levels.

Direct and Indirect Remuneration (DIR) fees are retroactive charges that PBMs impose on pharmacies, often six months or more after a Medicare Part D prescription has been filled. Between 2010 and 2020, the total amount of DIR fees collected from pharmacies grew by 107,400% according to the Centers for Medicare and Medicaid Services. These fees function as clawbacks: a pharmacy fills a prescription, receives a reimbursement at the point of sale, and then months later the PBM takes back a portion of that reimbursement based on opaque performance metrics that the pharmacy had no ability to predict at the time of dispensing. This creates an accounting nightmare that makes it impossible for independent pharmacies to know whether they are profitable on any given prescription until months after the fact. A pharmacy may fill a prescription believing it will break even, only to discover six months later that a DIR fee has turned that transaction into a net loss. Multiply this uncertainty across thousands of prescriptions per month and the result is a business that cannot reliably forecast its own cash flow. For small independent pharmacies operating on margins of 1-2%, a single large DIR fee clawback can wipe out an entire quarter's profit. CMS attempted to reform DIR fees effective January 1, 2024, requiring that all DIR fees be applied at the point of sale rather than retroactively. But the reform had unintended consequences: while retroactive clawbacks were eliminated, the point-of-sale adjustments often resulted in even lower upfront reimbursements, and PBMs introduced new fee categories -- Generic Effective Rate (GER) and Brand Effective Rate (BER) recoupments -- that function similarly to the old DIR fees under different names. This problem persists because the regulatory framework gives PBMs broad discretion to define performance metrics and fee structures. The pharmacy has no meaningful ability to negotiate these terms -- it either accepts the PBM's contract or loses access to that PBM's patient network. The power asymmetry is total: three PBMs control 80% of the market, and a pharmacy that refuses one PBM's terms loses roughly a quarter of its potential customers.

The three largest pharmacy chains in America are simultaneously shrinking. Walgreens announced plans to close 500 locations in 2025 and another 700 over the following two years. CVS closed 900 stores between 2022 and 2024 and plans to close 235 more by the end of 2025. Rite Aid, after a second bankruptcy filing, has ceased operations entirely. Combined, this represents the elimination of over 2,100 pharmacy locations by the country's largest chains -- and these are in addition to the thousands of independent pharmacies that have already closed. The chain pharmacy closures hit differently than independent closures because chains were supposed to be the resilient backbone of medication access. When an independent pharmacy closes, the conventional wisdom has been that a chain will fill the gap. But when the chains themselves are contracting, there is no backstop. Communities that already lost their independent pharmacies to chain competition in the 2000s and 2010s are now losing the chains too, leaving them with nothing. These closures are driven by a combination of factors that make the retail pharmacy model increasingly unviable. Declining prescription reimbursements from PBMs, competition from mail-order and Amazon Pharmacy, rising labor costs, increased shoplifting, and the end of COVID-era vaccination and testing revenue have all squeezed margins. Walgreens reported operating losses of $6.2 billion in fiscal 2024. The pharmacies that remain open are understaffed, with reduced hours, longer wait times, and higher error rates. This problem persists because the retail pharmacy is caught in a structural vise: PBMs squeeze reimbursement from above while operating costs rise from below. Mail-order captures the profitable, high-volume maintenance medications, leaving brick-and-mortar pharmacies with the complex, low-margin prescriptions. The business model that sustained pharmacy chains for decades -- using front-of-store retail sales to subsidize pharmacy operations -- has been gutted by e-commerce. No amount of operational efficiency can fix a model where revenue per prescription is below the cost of dispensing.

Pharmacy closures are not distributed equally across communities. USC research found that retail pharmacy closure rates were 37.5% in Black neighborhoods and 35.6% in Latino neighborhoods, compared to 27.7% in predominantly white neighborhoods. The disparity is even starker when income is factored in: 47.7% of low-income Black neighborhoods became pharmacy deserts compared to 40.3% of low-income white neighborhoods. Over 80% of Black and Hispanic residents nationally live in areas where pharmacy deserts are more common. This racial disparity in pharmacy access compounds existing health disparities that are already costing lives. Black Americans have higher rates of hypertension, diabetes, and cardiovascular disease -- conditions that require consistent medication adherence to manage. When the nearest pharmacy is miles away and requires a car, a bus transfer, or a half-day off work, prescriptions go unfilled. Unfilled prescriptions become uncontrolled blood pressure, diabetic crises, and preventable strokes. The pharmacy desert does not create these diseases, but it removes the most accessible intervention point for managing them. The racial dimension is not coincidental. Historically redlined neighborhoods have fewer healthcare facilities of all kinds, including pharmacies. Chain pharmacies make location decisions based on profitability metrics that favor affluent, high-traffic areas. When chains like Rite Aid go bankrupt or CVS and Walgreens close hundreds of stores, the locations selected for closure are disproportionately in lower-income, majority-minority neighborhoods where per-prescription revenue is lower and shoplifting losses may be higher. This problem persists because pharmacy location decisions are driven entirely by private-sector economics with no public obligation to maintain access equity. Unlike hospitals, which face community benefit requirements and certificate-of-need regulations in many states, pharmacies can open and close at will. There is no regulatory mechanism to prevent a pharmacy desert from forming in a vulnerable community, and no public funding mechanism to sustain pharmacy access where the market will not.

Over 630 rural counties in the United States have no retail pharmacy at all. Nearly 90% of people living in pharmacy deserts are in rural areas, with 56.8% of all rural residents lacking access to a nearby pharmacy. States like Oregon have seen their pharmacy desert populations surge by 56% between 2021 and 2025, from 600,000 to 937,000 residents. Ohio's pharmacy desert population grew by 410,000 in the same period, reaching nearly 2 million. In rural communities, the local pharmacy is not just a dispensary -- it functions as the primary healthcare access point for the entire community. Rural residents visit their community pharmacy 14 times per year compared to five visits to their primary care physician. The pharmacist is often the first person consulted about symptoms, drug interactions, or whether something warrants a doctor visit. When this access point disappears, the healthcare safety net develops a gaping hole that no telemedicine platform or mail-order service can fully patch. The health consequences cascade. COVID-19 vaccination coverage was 6.8 percentage points lower in rural counties (38.9%) than urban counties (45.7%), driven in part by the fact that 111 rural counties -- mostly between the Mississippi River and the Rocky Mountains -- had no pharmacy capable of administering vaccines. Rural areas also dispense naloxone at much lower rates than urban areas despite having higher opioid prescribing rates, meaning the opioid crisis hits harder precisely where pharmacy access is weakest. This problem persists because rural pharmacies operate on razor-thin margins serving small populations, and PBM reimbursement rates are set nationally without adjusting for the higher per-unit costs of serving low-density areas. When a rural pharmacy closes, there is no market incentive for another to open in its place. The population density that made the pharmacy marginally viable does not increase after closure -- it often decreases as healthcare access loss accelerates rural population decline.

The three largest pharmacy benefit managers -- CVS Caremark, Express Scripts, and OptumRx -- control nearly 80% of the approximately 6.6 billion prescriptions dispensed annually in the United States. These vertically integrated conglomerates own or are affiliated with their own mail-order and retail pharmacies, and they systematically set reimbursement rates that drive independent competitors out of business. Some prescriptions cost $100 to fill, but PBMs reimburse as little as $4, creating an impossible economic equation for independent pharmacies. This is not a market inefficiency -- it is a structural feature of vertical integration. When a PBM owns the insurance plan, the formulary, and the pharmacy, it can direct prescriptions to its own affiliated pharmacies while starving independent pharmacies of volume and margin. The FTC's 2024 staff report confirmed that PBMs engage in practices that squeeze independent pharmacies, including steering patients to PBM-owned pharmacies and imposing onerous contract terms. Nearly 4,000 pharmacy closures since 2019 have been attributed to these vertically integrated networks. The patients who suffer most are in rural and underserved communities where independent pharmacies are often the only option. When these pharmacies close, there is no CVS or Walgreens waiting to fill the gap. The community simply loses pharmacy access entirely. USC research found that independent pharmacies were twice as likely to close as chain stores, and closure rates were highest in Black neighborhoods (37.5%) and Latino neighborhoods (35.6%) compared to predominantly white neighborhoods (27.7%). This problem persists because PBMs operate with minimal transparency and enormous lobbying power. Congress attempted PBM reform in 2024, but it was blocked. The American Economic Liberties Project documented that 326 additional pharmacies closed in the period after PBM reform was killed. Some states have begun acting independently -- Arkansas became the first state to ban PBM-owned pharmacies -- but federal reform remains stalled despite bipartisan support.